October 29, 2025 — Leads & Copy — Mind Medicine (MindMed) Inc. (NASDAQ:MNMD) announced its intention to offer common shares and pre-funded warrants in an underwritten public offering, subject to market conditions. The offering includes an option for underwriters to purchase additional shares within 30 days.
The biopharmaceutical company plans to use net proceeds to fund research and development, working capital, and general corporate purposes. A portion may be used for acquisitions.
Jefferies LLC, Leerink Partners, and Evercore ISI are the joint bookrunning managers for the offering, which is subject to market conditions. The securities are offered under a shelf registration statement filed with the SEC.
A preliminary prospectus supplement will be filed with the SEC and SEDAR+ and available on their websites. Copies can be obtained from Jefferies LLC, Leerink Partners LLC, or Evercore Group L.L.C.
This announcement does not constitute an offer to sell securities.
MindMed is focused on developing novel product candidates to treat brain health disorders, trading on NASDAQ under the symbol MNMD.
Contact: Jefferies LLC, Attention: Equity Syndicate Prospectus Department, 520 Madison Avenue, New York, NY 10022, by telephone at (877) 821-7388 or by email at Prospectus_Department@Jefferies.com; Leerink Partners LLC, Attention: Syndicate Department, 53 State Street, 40th Floor, Boston, MA 02109, by telephone at (800) 808-7525, ext. 6105, or by email at syndicate@leerink.com; or Evercore Group L.L.C., Attention: Equity Capital Markets, 55 East 52nd Street, 35th Floor, New York, NY 10055, by telephone at (888) 474-0200, or by email at ecm.prospectus@evercore.com.
Source: MindMed
